Diabetes in primary care: prospective associations between depression, nonadherence and glycemic control

Dirmaier, Jörg; Watzke, Birgit; Koch, Uwe; Schulz, Holger; Lehnert, Hendrik; Pieper, Lars; Wittchen, Hans-Ulrich

Abstract: BACKGROUND Findings are inconsistent regarding the degree to which depression may exert a negative impact on glycemic control in patients with type 2 diabetes. We therefore aimed to examine the longitudinal relationship between depression, behavioral factors, and glycemic control. METHODS In a prospective component of a nationally representative sample, 866 patients with type 2 diabetes aged >or=18 years completed a standardized assessment including a laboratory screening, questionnaires, and diagnostic measures. Subsequent to baseline (t(0)), patients were tracked over a period of 12 months (t(1)). Depression was assessed according to DSM-IV and ICD-10 criteria. Glycemic control was determined by levels of glycosylated hemoglobin (HbA(1c)); a level of >or=7% was judged as unsatisfactory. Regression analyses were performed to analyze the prospective relationship between depression, medication adherence, diabetes-related health behavior, and HbA(1c). RESULTS Patients with depression at t(0) revealed increased rates of medication nonadherence (adjusted OR: 2.67; CI: 1.38-5.15) at t(1). Depression (adjusted regression coefficient: beta = 0.96; p = 0.001) and subthreshold depression (beta = 1.01; p < 0.001) at t(0) also predicted increased problems with diabetes-related health behavior at t(1). Adjusted ORs for poor glycemic control (HbA(1c) >or=7%) at t(1) were also increased for patients with baseline depression (2.01; CI: 1.10-3.69). However, problems with medication adherence as well as problems with diabetes-related health behavior at t(0) did not predict poor glycemic control at t(1). CONCLUSIONS In a prospective representative study of patients with type 2 diabetes, baseline depression predicted problems with medication adherence, problems with health-related behaviors, and unsatisfactory glycemic control at follow-up.

DOI: https://doi.org/10.1159/000296135

Posted at the Zurich Open Repository and Archive, University of Zurich

Published Version

Originally published at:

DOI: https://doi.org/10.1159/000296135
Diabetes in Primary Care: Prospective Associations between Depression, Nonadherence and Glycemic Control

Jörg Dirmaier, Birgit Watzke, Uwe Koch, Holger Schulz, Hendrik Lehnert, Lars Pieper, Hans-Ulrich Wittchen

Department of Medical Psychology, University Medical Center Hamburg-Eppendorf, Hamburg, First Department of Medicine, University of Lübeck, Lübeck, and Institute of Clinical Psychology and Psychotherapy, Center of Clinical Epidemiology and Longitudinal Studies (CELOS), Technische Universität Dresden, Dresden, Germany; Warwick Medical School, University Hospital of Coventry, Coventry, UK

Abstract
Background: Findings are inconsistent regarding the degree to which depression may exert a negative impact on glycemic control in patients with type 2 diabetes. We therefore aimed to examine the longitudinal relationship between depression, behavioral factors, and glycemic control.

Methods: In a prospective component of a nationally representative sample, 866 patients with type 2 diabetes aged ≥18 years completed a standardized assessment including a laboratory screening, questionnaires, and diagnostic measures. Subsequent to baseline (t₀), patients were tracked over a period of 12 months (t₁). Depression was assessed according to DSM-IV and ICD-10 criteria. Glycemic control was determined by levels of glycosylated hemoglobin (HbA₁c); a level of ≥7% was judged as unsatisfactory. Regression analyses were performed to analyze the prospective relationship between depression, medication adherence, diabetes-related health behavior, and HbA₁c.

Results: Patients with depression at t₀ revealed increased rates of medication non-adherence (adjusted OR: 2.67; CI: 1.38–5.15) at t₁. Depression (adjusted regression coefficient: β = 0.96; p = 0.001) and sub-threshold depression (β = 1.01; p < 0.001) at t₀ also predicted increased problems with diabetes-related health behavior at t₁. Adjusted ORs for poor glycemic control (HbA₁c ≥7%) at t₁ were also increased for patients with baseline depression (2.01; CI: 1.10–3.69). However, problems with medication adherence as well as problems with diabetes-related health behavior at t₀ did not predict poor glycemic control at t₁.

Conclusions: In a prospective representative study of patients with type 2 diabetes, baseline depression predicted problems with medication adherence, problems with health-related behaviors, and unsatisfactory glycemic control at follow-up.

Introduction

There is a two- to three-fold risk of depression in patients with type 2 diabetes, suggesting that depression is strongly related to this disease [1]. Comorbid depression in diabetes was thereby found to be associated with in-
creased instances and severities of medical complications [2], poorer overall health status [3], more absences from work [4], higher health care costs [5], and increased mortality [6], as opposed to diabetes without depression.

Recent research suggests a bidirectional association between diabetes and depression [7]. However, the biological and behavioral mechanisms of this association remain unclear [8]. In addition to the direct negative physiological effects on glucose metabolism (activation of the neuroendocrine and inflammatory responses [9]) and behavioral risk factors such as obesity-promoting health behaviors (e.g., physical inactivity, hypercaloric diets), depression produces an especially poor adherence to a variety of self-care responsibilities (e.g., medications or modification of health behaviors), which is considered to be related to the state of glycemic control [10].

High glycosylated hemoglobin (HbA1c) is an index of long-term glycemic control and an independent predictor of diabetes. High levels of HbA1c are associated with an increased risk of medical complications, mortality, and poor quality of life in patients with type 2 diabetes [11]. However, previous results regarding the association of depression and HbA1c in patients with type 2 diabetes are inconsistent [12–14], which is surprising in light of the strong association between depression and diabetes. Moreover, in the field of primary care, these studies have been cross-sectional.

Given these inconsistent results and the lack of prospective examinations of the effect of depression on HbA1c and relevant behavioral mechanisms (adherence to medications and health behaviors) linking these associations, we used a nationally representative sample of primary care patients with type 2 diabetes to investigate: (1) the effects of depression on adherence to medical recommendations (concerning medication and health behavior), and (2) the effects of depression and adherence to medical recommendations (concerning medication and health behavior) on HbA1c in primary care patients with type 2 diabetes over a 12-month follow-up period.

**Patients and Methods**

**Sample**

Analyses were based on the DETECT (Diabetes Cardiovascular Risk Evaluation: Targets and Essential Data for Commitment of Treatment) study, which is a cross-sectional clinical-epidemiological study with a prospective-longitudinal component in primary care in Germany. Data collection was performed between September 2003 and December 2004. A complete description of the study methodology and sampling has been published elsewhere [15].

In brief, the DETECT study used a random subsample of 7,519 patients of the core survey, which consisted of 55,518 unselected consecutive patients (aged ≥18 years) attending 3,188 primary care settings at baseline (t0). It utilized a standardized assessment, including questionnaires for patients and physicians, and an extensive laboratory screening program with follow-up (t1) after 12 months. At t0, data from 6,627 (93.1%) patients were collected, including 866 patients attending 466 different primary care settings who had been diagnosed with type 2 diabetes and had a valid score for depression.

In the later analyses, the data were weighted to adjust for the regional distribution of general practitioners and internists to obtain a representative sample of German primary care patients. The study sample of doctors can therefore be regarded as nationally representative in terms of regional distribution, age, years of experience, specialty orientation, and patient load per day [15]. The longitudinally investigated cohort was additionally adjusted to the morbidity status, age, and gender distribution of the main study. Moreover, there were no noteworthy differences in the characteristics of those patients analyzed only at baseline and the subsample followed up for 1 year [15]. The 866 patients for whom a valid score for depression was available did not differ from the 917 patients diagnosed with type 2 diabetes with regard to sociodemographic or clinical variables. Therefore, the patient sample can also be regarded as representative of primary care settings in Germany [15].

The study was approved by the local ethics committee of the Technical University Dresden (AZ: EK149092003; 16.09.2003).

**Assessment of Depression**

The Depression Screening Questionnaire (DSQ) developed by Wittchen and Perkonigg [16] is a well-established and frequently used instrument in large-scale studies in primary care [17]. This self-report measure consists of 10 items with a 3-point scale with 0 (never) through 1 (on some days) to 2 (on the majority of days) referring to the preceding 2 weeks. The diagnosis of depression can be made according to the ICD-10 criteria: at least 3 questions must be answered with ‘on the majority of days’ and the total score must be ≥7. The DSQ has a high internal consistency (Cronbach’s α = 0.83 [18]), and the 1-week test-retest reliability found a k value of 0.82 [16]. The validity of the diagnosis of major depression is very high compared to the Composite International Diagnostic Interview [19]: k = 0.89 for DSM-IV and k = 0.84 for ICD-10 [16]. In order to account for recent findings showing that subthreshold levels of depression also have a negative impact on health outcomes in patients with type 2 diabetes [20], the calculated total scores were grouped into 3 categories: 0–4 points indicated no depression, 5–7 points indicated subthreshold depression, and ≥7 points indicated depression. The cut-off of ≤4 points was chosen for patients whose depressive symptomatology is not sufficient for the subthreshold category, taking into account 4 ‘somatic’ items that diabetic patients might experience due to resulting physical limitations (psychomotor retardation, sleep disturbance, loss of sexual desire, loss of appetite or weight loss).

**Assessment of Adherence**

Medication nonadherence was assessed by responses to the question ‘How often did you have problems taking your medications as prescribed by the physician?’ based on a 4-level response scale (almost never/rarely/often/always) during the last 4 weeks.
Due to skewed data, the values were split into 2 categories: ‘nearly never’ versus ‘rarely/often/always’. Nonadherence with health behavior during the preceding 4 weeks was assessed by 5 items covering the frequency of problems with diet (2 items: healthy diet plans, weight control/reduction), stopping smoking, alcohol consumption, and adequate physical activity, with 4 response possibilities (never/rarely/often/almost daily). The values were added to a total score. Both assessments (adherence to medication/health behaviors) have high face validity as they directly capture observable behavior patterns.

Assessment of Diabetes and HbA1c
Type 2 diabetes was assumed when the diagnosis was rated as ‘definite’ (vs. ‘suspected’ or ‘no’) in the questionnaire answered by the physicians. HbA1c values were used as an indicator of glycemic control. The general goal in the treatment of diabetes is a HbA1c values used as an indicator of glycemic control. The general goal in the treatment of diabetes is a HbA1c of <7% [21]. Therefore, HbA1c values were classified as ≥7% (unsatisfactory glycemic control) and as <7% (good glycemic control).

Statistical Analysis
χ² or t tests were used to test for differences between type 2 diabetes patients with various levels of depression.

Logistic regression was used to analyze the effects of depression on problems with medication adherence and glycemic control. Linear regression models were employed to investigate the influence of depression on problems with health behavior. The odds ratios (ORs) and the regression coefficients (β) were calculated with 95% CI. All models were adjusted for gender, age, marital and employment status, education, physical activity, BMI, smoking, drinking, duration of diabetes, and type of diabetes treatment.

Adjustments were also made to account for the stratified sampling design and the resulting possibility of clustered observations: patients may be clustered in primary care units so that correlations within these units can be assumed. Therefore, we calculated CIs for all regression analyses applying the Huber-White sandwich method [22].

Power calculations (χ² test of trend in proportions based on the logistic model) revealed that given a sample size of 866 (α = 0.05, two-sided), an OR of 2 for poor glycemic control is detectable with a power of 91%. For all analyses, the level of significance was set at p < 0.05. We employed the statistical package STATA 9.1.

Results
For the prospective cohort study, the sociodemographic, behavioral, and clinical characteristics of the type 2 diabetes patients with no depression, subthreshold depression, or depression are compared in table 1. A total of 179 patients (20.7%) had subthreshold depression, and 102 (11.7%) of the 866 patients suffered from depression. Compared to patients with no depression, patients with depression as well as patients with subthreshold depression were more frequently women with fewer weekly physical activities. Furthermore, patients with depression were younger, more likely to be smokers, less likely to drink alcohol, and were more often treated with insulin compared to patients with no depression. Patients with depression were also younger and more likely to be smokers than patients with subthreshold depression.

Association of Depression, Medication Adherence, and Health Behavior at Baseline
At baseline, when adjusting for the covariates listed in table 1, patients with depression exhibited a higher risk (OR = 4.45; CI: 2.52–7.84; p < 0.001) of problems with medication adherence. Unfavorable health behavior was associated with subthreshold depression (β = 0.68; CI: 0.29–1.08) and depression (β = 1.47; CI: 0.96–1.98; R² = 0.41) at baseline. Having subthreshold depression was not associated with glycemic control at baseline. However, among those who had depression, the odds of problems with glycemic control at baseline were elevated (OR = 1.71; CI: 1.01–2.90; p < 0.05). There were no associations between glycemic control and having problems with medication adherence or health behavior.

Prediction of Glycemic Control, Medication Adherence, and Health Behavior
The prospective association between depression (t₀) and medication adherence and health behavior at follow-up (t₁) is shown in table 2. Having subthreshold depression (t₀) is not associated with medication adherence problems at t₁. However, among those who had depression, the odds of problems with medication adherence (adjusted for all covariates listed in table 1) are elevated at t₁ (OR = 2.67; CI: 1.38–5.15; p = 0.003). Table 2 also shows the crude and adjusted standardized regression coefficients for the association of depression (t₀) and problems with health behavior (t₁). In the adjusted model, having more problems with health behavior is associated with harboring subthreshold depression (β = 1.01; CI: 0.62–1.40) and depression (β = 0.96; CI: 0.40–1.52; R² = 0.30) at baseline.

The association between depression (t₀) and HbA1c at t₁ is also shown in table 2. Having subthreshold depression (t₀) is not associated with glycemic control at t₁. However, among those who were classified as depressed, the adjusted odds of problems with glycemic control are elevated at t₁ (OR = 2.01; CI: 1.10–3.69; p = 0.023). These analyses were also run separately for the association of medication adherence and health behavior (t₀) on glycemic control at t₁. After adjusting for the covariates, there are no significant associations between problems with medication adherence and health behavior (t₀) and prob-
Table 1. Sociodemographic and clinical baseline characteristics of primary care patients by severity of depression (n = 866)

<table>
<thead>
<tr>
<th>Variables</th>
<th>No depression (n = 585)</th>
<th>Subthreshold depression (n = 179)</th>
<th>Depression (n = 102)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female gender</td>
<td>266 (45.5)</td>
<td>100 (55.6)^a</td>
<td>57 (55.9)^a</td>
</tr>
<tr>
<td>Age, years</td>
<td>66.8 ± 9.7</td>
<td>66.8 ± 10.0</td>
<td>63.5 ± 11.9^b,d</td>
</tr>
<tr>
<td>Years of education</td>
<td>9.2 ± 1.9</td>
<td>9.2 ± 1.7</td>
<td>9.2 ± 1.8</td>
</tr>
<tr>
<td>Marital status</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Single</td>
<td>24 (4.2)</td>
<td>10 (5.7)</td>
<td>6 (5.9)</td>
</tr>
<tr>
<td>Married</td>
<td>400 (69.6)</td>
<td>110 (62.5)</td>
<td>67 (66.3)</td>
</tr>
<tr>
<td>Divorced/widowed</td>
<td>151 (26.3)</td>
<td>56 (31.8)</td>
<td>28 (27.7)</td>
</tr>
<tr>
<td>Retired/unemployed/housewife</td>
<td>480 (82.9)</td>
<td>161 (90.4)^a</td>
<td>90 (89.1)</td>
</tr>
<tr>
<td>Smoking</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nonsmoker</td>
<td>463 (87.4)</td>
<td>147 (89.1)</td>
<td>78 (83.0)</td>
</tr>
<tr>
<td>Smoker</td>
<td>67 (12.6)</td>
<td>18 (10.9)</td>
<td>16 (17.0)</td>
</tr>
<tr>
<td>Amount of drinking</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Less than 2 times a month</td>
<td>267 (48.5)</td>
<td>94 (54.7)</td>
<td>68 (68.7)</td>
</tr>
<tr>
<td>Less than 2 times a week</td>
<td>111 (20.1)</td>
<td>37 (21.5)</td>
<td>14 (14.1)</td>
</tr>
<tr>
<td>3 or more times a week</td>
<td>137 (31.4)</td>
<td>41 (23.8)</td>
<td>17 (17.2)</td>
</tr>
<tr>
<td>BMI</td>
<td>29.4 ± 4.7</td>
<td>30.1 ± 5.1</td>
<td>30.5 ± 5.8</td>
</tr>
<tr>
<td>Weekly physical activities &lt;2 h</td>
<td>161 (30.1)</td>
<td>75 (46.3)^c</td>
<td>41 (47.7)^c</td>
</tr>
<tr>
<td>Duration of diabetes, years</td>
<td>7.6 ± 6.7</td>
<td>8.6 ± 7.7</td>
<td>8.4 ± 7.4</td>
</tr>
<tr>
<td>Diabetes treatment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None or diet</td>
<td>169 (28.9)</td>
<td>46 (25.6)</td>
<td>29 (28.7)</td>
</tr>
<tr>
<td>Oral hypoglycemic</td>
<td>352 (60.2)</td>
<td>104 (57.8)</td>
<td>51 (50.5)</td>
</tr>
<tr>
<td>Insulin or insulin + oral hypoglycemic</td>
<td>64 (10.9)</td>
<td>30 (16.7)</td>
<td>21 (20.8)</td>
</tr>
</tbody>
</table>

Data are presented as means ± SD or number of patients with percentages in parentheses.

^a p < 0.05, ^b p < 0.01, ^c p < 0.001 vs. no depression, ^d p < 0.01 vs. subthreshold depression.

Table 2. OR for problems with medication adherence and glycemic control, and standardized regression coefficients (β) for problems with health behavior

<table>
<thead>
<tr>
<th>Problems with medication adherence (t1)</th>
<th>Problems with health behavior (t1)</th>
<th>Problems with glycemic control (HbA1c ≥7%) (t1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>OR crude p</td>
<td>OR adjusted^2 p</td>
<td>OR crude p</td>
</tr>
<tr>
<td>No depression (t0)</td>
<td>ref.</td>
<td>ref.</td>
</tr>
<tr>
<td>Subthreshold depression (t0)</td>
<td>1.4 (1.0–2.2)</td>
<td>0.14</td>
</tr>
<tr>
<td>Depression (t0)</td>
<td>2.9 (1.7–4.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Problems with medication adherence (t0)</td>
<td>1.4 (1.0–2.1)</td>
<td>0.07</td>
</tr>
<tr>
<td>Problems with health behavior (t0)</td>
<td>1.0 (1.0–1.1)</td>
<td>0.18</td>
</tr>
</tbody>
</table>

^95% CI are given in parentheses.

1 HbA1c ≥7%. ^2 Adjusted for gender, age, marital and employment status, education, physical activity, BMI, smoking, drinking, duration of diabetes, and type of diabetes treatment.
lems with glycemic control at $t_1$. The association of medication adherence and health behavior ($t_0$) on glycemic control at $t_1$ was additionally tested for the subsample of insulin-treated diabetics. Again, there are no significant associations between problems with medication adherence (OR: 1.31; CI: 0.86–1.98; $p = 0.210$) and health behavior (OR: 0.99; CI: 0.91–1.08; $p = 0.844$) at $t_0$ and problems with glycemic control at $t_1$.

Discussion

As depressive symptoms occur frequently in patients with type 2 diabetes, it is important to understand how depression affects the treatment of diabetes. Therefore, we analyzed a large sample to assess prospective associations between depression, adherence, and glycemic control in patients with type 2 diabetes.

This study showed that depression, but not subthreshold depression, is prospectively associated with higher HbA1c levels over a 12-month follow-up. To our knowledge, this is the first study using a nationally representative cohort of adults in primary health care systems that showed a prospective relationship between depression and glycemic control.

It is still uncertain from current research whether coexisting depression affects glycemic control. Our study found that for patients with type 2 diabetes and coexisting depression at baseline, the odds of HbA1c ≥7% versus HbA1c <7% at follow-up were doubled, even when various other factors were controlled. This study thus confirmed existing findings from studies using cross-sectional designs indicating that depression is related to glycemic control [23]. In accordance with prior research [24], there was no prospective relationship between subthreshold depression and both medication adherence and HbA1c levels. As shown by Fisher et al. [25], subthreshold or nonclinical levels of depression are more strongly correlated with sources of distress resulting from diabetes specifically, such as diabetes-related health care and economic, social, and family difficulties [25], than with clinical depression. This could be a possible reason for the lack of associations between subthreshold depression and HbA1c levels.

Depression at baseline predicts more problems with medication adherence and health behavior at follow-up among patients with type 2 diabetes. According to Cramer [26], medication adherence is defined as ‘the extent to which a patient acts in accordance with the prescribed interval and dose of a dosing regimen’, whereas medication persistence is defined as ‘the duration of time from initiation to discontinuation of therapy’. Our findings regarding adherence to medication and health behavior are consistent with previous cross-sectional research [23, 27]. Additionally, earlier research has shown that even subclinical levels of depression are associated with nonadherence [10], although again only cross-sectionally. Our study thus confirms these findings through a prospective study design, which indicates that even low levels of depressive symptomatology represent a major prognostic risk factor for poor medication adherence and poor health behavior.

Adherence to self-care behavior – like medication intake, dietary guidelines, or exercise – is crucial in the treatment of diabetes and appears to be an important contributor to glycemic control [27]. Inconsistent with these findings, adherence to medication and health behavior at baseline did not predict problems with glycemic control (HbA1c level ≥7%). This may be a function of different or imprecise methodology for measuring adherence (e.g. single-item measurement of medication adherence), differences in the complexity of self-care regimens, different study designs, and social desirability or recall biases. In addition, our data show that there are low baseline values for medication adherence as well as health behavior, which might result from sample-specific characteristics such as older age and long duration and treatment of diabetes. Being treated for diabetes for several years might have improved medication adherence, and, with older age, the subjective standard for health behavior might decrease. Thus, the variable probably did not provide enough variance in its distribution. It is also possible that adherence and health behavior improved over the course of the year, e.g. due to interventions of the responsible physician. Furthermore, previous research has shown that the strongest associations between adherence and glycemic control exist in insulin-treated diabetic patients [28], and focusing on this subsample may have revealed a stronger relationship. Testing this hypothesis did not show any significant results, however, probably because the proportion of subjects with insulin treatment was comparatively low [23] in our patients.

Several limitations relevant to interpreting the findings have to be mentioned. One limitation was the use of self-report data on medication adherence and health behavior, because of a resulting tendency to overestimate adherence due to recall biases and social desirability. However, a meta-analysis comparing self-report measurements with more objective methods such as electronic monitoring showed that self-report measurements have
sufficient validity and reliability [29]. In addition, electronic monitoring is associated with high costs and therefore not appropriate in large-scale studies. Second, measuring medication adherence with a single item represents another limitation of the study. Yet there are some indications that single-item measurement has sufficient predictive value and concordance with scales including multiple items to measure adherence [30]. Third, we did not have any measurements for diabetes-specific self-care, such as self-monitoring of blood glucose, foot care or dietary habits. This was due to the study design, in which data for several chronic diseases were collected, which prevented the use of diabetes-specific instruments. Moreover, there was no data on the course or treatment of depression during the 12-month follow-up period. However, depression has been shown to be persistent in nearly three quarters of diabetic adults at 6-month follow-up [31], which is consistent with our data where depression was persistent over the 12-month follow-up period in half of the patients. Because depression among primary care patients with diabetes is predominantly unrecognized and untreated, the findings probably would be similar even when treatment was accounted for. During a 12-month period, less than half of the patients with depression were recognized, less than half of them received antidepressant descriptions, and only about 7% received adequate psychotherapeutic treatment [32]. By comparison, in our sample merely one third of the depressed patients were recognized as depressed by their physicians, and therefore the rate of depression-related treatment is presumed to be correspondingly low. Measuring depression with the DSQ may have resulted in an overestimation of depressive symptoms because diabetes and other medical comorbidities in primary care frequently involve somatic symptoms that were probably attributed to depression. However, the 11.8% rate of major depression found in this sample is even lower than the overall prevalence of depression in patients with diabetes of 17.6% found in a prior meta-analysis [1]. Nevertheless, cross-validation in diabetic patients with a well-validated screening instrument for depression for the use in primary care settings may additionally be required.

This study has several major strengths. First, the studied sample constituted a large nationally representative cohort of adults in primary health care. Therefore, the generalizability of the results to countries providing similar health care services is very high. Second, its prospective study design enables causal inferences regarding HbA1c levels and depression. Third, the study combined multiple data perspectives resulting in a broad frame-work; self-reports, data collected from the physician, and the availability of laboratory data HbA1c provided a large number of diabetes-related variables.

In conclusion, the results of this study of adults with type 2 diabetes show that there is a significant prospective relationship between depression and glycemic control, indexed by HbA1c, and that even subthreshold depression is associated to problems with adherence to treatment recommendations over a 12-month follow-up. These data clearly emphasize the importance of depression in the treatment of adults with type 2 diabetes.

Appendix: DETECT Members

Principal investigator: Prof. Dr. H.-U. Wittchen. Staff members: Dipl. Psych. L. Pieper, Dipl. Math. J. Klotsche, Dipl. Psych. T. Eichler, Dipl. Psych. Dr. H. Glaesmer, E. Katze, Dipl. Psych. A. Bayer, Dipl. Psych. A. Neumann. Steering board: Prof. Dr. H. Lehert (Lübeck, Coventry), Prof. Dr. G.K. Stalla (München), Prof. Dr. M.A. Zeiher (Frankfurt) Prof. Dr. M. Wehling (Mannheim). Advisory board: Prof. Dr. W. Mārz (Graz/Heidelberg), Prof. Dr. S. Silber (München), Prof. Dr. U. Koch (Hamburg), PD Dr. D. Pittrow (München/Dresden).

Acknowledgement

DETECT (Diabetes Cardiovascular Risk Evaluation: Targets and Essential Data for Commitment of Treatment) is supported by an unrestricted educational grant from Pfizer, Karlsruhe, Germany.

References


